Neurocrine is committed to transparency in its interactions. Neurocrine commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency. Neurocrine has published details of its transfers of value required under the ABPI Code on the ABPI website and below. Disclosures prior to 2025 are reported under the legacy name Diurnal.
Where individual countries have other transparency regulations, Neurocrine also complies with the EFPIA through this route.
Neurocrine is committed to transparency in clinical trials and publishes the protocols and results of its clinical trials on the website www.clinicaltrials.gov
This site is for UK Healthcare Professionals. By clicking you are acknowledging that you are a UK Healthcare Professional